Catalyst
Slingshot members are tracking this event:
Acadia (ACAD) Commences Phase 3 Trial Evaluating Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
ACAD |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 03, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Trial Initiation, Pimavanserin, Adjunctive Treatment, Schizophrenia